Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)
March 15, 2021 08:43 AM EDTUpdated March 19, 12:10 PM
Deals

Gilead, Mer­ck put aside ri­val­ry to chal­lenge Glax­o­SmithK­line for long-act­ing HIV meds

Jason Mast

Editor

Joan But­ter­ton was sit­ting 30,000 feet above the At­lantic, fly­ing to a con­fer­ence in Eu­rope, when the Mer­ck sci­en­tist seat­ed next to her start­ed gush­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times